News
StockStory.org on MSN3d
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.
Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In ...
This was the stock's second consecutive day of losses.
Explore more
The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...
AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...
6don MSN
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer
Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies.
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.
The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results